🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 45826J105
- Market Cap
- Mid Cap
- IPO
- 5/5/2016 · $18.00/share
Business: Intellia Therapeutics, Inc. is a leading gene editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course.
Company Contact
- CEO
- Hohn Leonard
- CFO
- Edward Dulac
- Headquarters
- 40 Erie Street, Suite 130, Cambridge, MA 02139
- Phone
- 857-285-6200
- Investor Relations
- Brittany Chaves · 646-378-2942 · brittany.chaves@intelliatx.com